CHINA PHARMA HOLDINGS, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.1M | $4.5M | $7.0M | $8.1M | $9.6M | $10.9M | $10.9M | $12.3M |
| Cost of Revenue | $4.3M | $6.5M | $7.3M | $8.6M | $9.3M | $8.9M | $9.4M | $10.4M |
| Gross Profit | $-132.0K | $-2.0M | $-281.1K | $-493.9K | $349.3K | $2.0M | $1.5M | $2.0M |
| Gross Margin | -3.2% | -43.8% | -4.0% | -6.1% | 3.6% | 18.0% | 13.6% | 16.0% |
| Operating Expenses | ||||||||
| Research & Development | $280.9K | $283.9K | $240.1K | $185.9K | $319.0K | $378.0K | $229.6K | $172.4K |
| SG&A Expense | $2.5M | $1.8M | $1.5M | $1.9M | $1.7M | $1.8M | $2.3M | $1.9M |
| Operating Income | $-3.2M | $-4.6M | $-2.8M | $-3.5M | $-2.9M | $-2.6M | $-20.4M | $-10.4M |
| Operating Margin | -78.2% | -101.3% | -39.2% | -43.8% | -29.7% | -23.7% | -186.8% | -84.7% |
| Interest Expense | $27.3K | $27.4K | $30.6K | $434.6K | $542.0K | $294.2K | $321.7K | $451.3K |
| Pretax Income | $-3.2M | $-4.7M | $-3.1M | $-4.0M | $-3.4M | $-2.9M | $-20.7M | $-10.9M |
| Income Tax Expense | — | — | — | — | — | — | — | $-110.0K |
| Net Income | $-3.2M | $-4.7M | $-3.1M | $-4.0M | $-3.4M | $-2.9M | $-20.7M | $-10.8M |
| Net Margin | -76.9% | -104.6% | -43.9% | -49.0% | -35.3% | -26.4% | -189.5% | -87.2% |
| EPS (Basic) | $-0.74 | $-1.36 | $-0.46 | $-0.63 | $-0.12 | $-0.01 | $-0.08 | $-0.04 |
| EPS (Diluted) | $-0.74 | $-1.36 | $-0.46 | $-0.63 | $-0.12 | $-0.01 | $-0.08 | $-0.04 |
| Shares Outstanding (Basic) | 4.3M | 3.5M | 6.8M | 6.3M | 27.7M | 273.5M | 261.5M | 261.5M |
| Shares Outstanding (Diluted) | 4.3M | 3.5M | 6.8M | 6.3M | 27.7M | 273.5M | 261.5M | 261.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |